. Prospective phase 2 trial of ixazomib after nonmyeloablative haploidentical peripheral blood stem cell transplant. Blood Adv. 2020;4(15):3669-3676.
Main menu
- About
- Chapters
- Cellular and nuclear reprogramming
- Ectoderm specification and differentiation
- Endoderm specification and differentiation
- Epigenetics
- Genomics and proteomics
- Germ cell and somatic stem cell biology in reproduction
- Manufacturing
- Mesoderm specification and differentiation
- Niche biology, homing, and migration
- Renewal
- Stem cell immunology
- Therapeutic prospects
- Tissue engineering
- Protocols
- StemLabs
- News & Profiles
- Journal Stream
- Forum